Cellectar Biosciences股票分割

鉅亨網,提供你最完整的cellectar biosciences inc_cellectar biosciences inc(clrb)股價flash線圖_投資全球讓你鉅亨。鉅亨網,提供你最完整的cellectar biosciences inc_cellectar biosciences inc(clrb)個股公司資料,中文新聞,英文新聞,股價走勢,技術線圖,財報。鉅亨網,提供你最完整的cellectar biosciences inc_cellectar biosciences inc(clrb)股價flash線圖_投資全球讓你鉅亨。

Company Contact Cellectar Biosciences, Inc. 100 Campus Drive, Suite 207 Florham Park, NJ 07932 T: 608-441-8120 F: 608-441-8121

Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the Company Contact Cellectar Biosciences, Inc. 100 Campus Drive, Suite 207 Florham Park, NJ 07932 T: 608-441-8120 F: 608-441-8121

Clinical Trials for CLR 131 CLR 131 is a small-molecule, cancer-targeting radiotherapeutic PDC designed to deliver cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. CLR 131 is our lead therapeutic PDC product candidate and is currently being evaluated in both Phase 1 and Phase 2 clinical studies.

Company Contact Cellectar Biosciences, Inc. 100 Campus Drive, Suite 207 Florham Park, NJ 07932 T: 608-441-8120 F: 608-441-8121

鉅亨網,提供你最完整的cellectar biosciences inc_cellectar biosciences inc(clrb)個股公司資料,中文新聞,英文新聞,股價走勢,技術線圖,財報。

Cellectar Biosciences is a clinical stage biopharmaceutical company that engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The Company offers product candidates for the treatment of relapse or refractory multiple myeloma, B-cell malignancies and micrometastatic disease, as well 13 Jul 2018 MADISON, Wis., July 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc . (Nasdaq:CLRB), a clinical-stage biopharmaceutical 診斷顯影劑研發廠Cellectar Biosciences, Inc.(CLRB.us)前身為Novelos Therapeutics, Inc.，於2014年2月更為現名。公司成立於2002年，總部設在威斯康辛州麥迪遜 Получите подробную информацию о акциях Cellectar Biosciences Inc (CLRB) включая Цену, Графики, Теханализ, Исторические данные, Отчеты и др. 3 Jun 2020 FLORHAM PARK, N.J., June 03, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage 14 May 2020 FLORHAM PARK, N.J., May 14, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical Cellectar Biosciences (CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

鉅亨網,提供你最完整的cellectar biosciences inc_cellectar biosciences inc(clrb)股價flash線圖_投資全球讓你鉅亨。

鉅亨網,提供你最完整的cellectar biosciences inc_cellectar biosciences inc(clrb)個股公司資料,中文新聞,英文新聞,股價走勢,技術線圖,財報。 CELLECTAR BIOSCIENCES INC_CELLECTAR BIOSCIENCES … 鉅亨網,提供你最完整的cellectar biosciences inc_cellectar biosciences inc(clrb)股價flash線圖_投資全球讓你鉅亨。鉅亨網,提供你最完整的cellectar biosciences inc_cellectar biosciences inc(clrb)個股公司資料,中文新聞,英文新聞,股價走勢,技術線圖,財報。鉅亨網,提供你最完整的cellectar biosciences inc_cellectar biosciences inc(clrb)股價flash線圖_投資全球讓你鉅亨。